Case Report

A Fatal Sepsis Caused by Hyaluronate Knee Injection: How Much the Medical History and the Informed Consent Might Be Important?

F. Manfreda,¹ G. Rinonapoli,¹,² A. Nardi,² P. Antinolfi,² and A. Caraffa¹,²

¹Department of Orthopedics and Traumatology, University of Perugia, Perugia, Italy
²Division of Orthopedics and Trauma Surgery, Santa Maria della Misericordia Hospital, Perugia, Italy

Correspondence should be addressed to F. Manfreda; francesco.manfreda@libero.it

Received 18 December 2016; Accepted 7 February 2017; Published 23 February 2017

Academic Editor: Bayram Unver

Copyright © 2017 F. Manfreda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The incidence of Osteoarthritis (OA) is gradually increasing worldwide due to two main reasons: longer life expectation and increased functional demand. Several treatment options have been proposed for this disease. Conservative treatment has the goal to improve the quality of life, reduce pain, and prevent the progression of the disease. Hyaluronate viscosupplementation is one of the most used infiltrative treatments for OA, but, despite its common use, clinical efficacy is still under question. Though adverse reactions for this medical option are actually rare, septic arthritis is a very scaring complication. We present a case report of a 59-year-old man who has been submitted to only one knee hyaluronate injection and consequently reported a severe septic arthritis and systemic sepsis, which lead to the death of the patient. We recommend producing correct guidelines for a clean aseptic procedure of injection to obtain proper consensus from the patient and to pay attention to his clinical history and comorbidities before acting any kind of invasive treatment, including joint injection.

1. Introduction

Knee Osteoarthritis (OA) is one of the commonest orthopedic pathologies [1] whose prevalence is increasing worldwide. This burden will continue to increase in the general population [2]; actually, it gives functional deficits in 10% of individuals over the age of 55 years [3]. Several treatments for OA have been proposed during the years in a very large range of strategies [4], including interventions to increase tolerance for functional activity, improve quality of life, prevent the disease, and stop its progression [5]. Among them, intra-articular injection is one of the most used treatments in order to reduce symptoms, both in early and in the severe stages of the disease [6].

Viscosupplementation with intra-articular hyaluronic acid was approved as a conservative option for OA in 1997 by FDA (Food and Drug Administration) [7, 8]. Important benefits for this kind of treatment have been proven in the last years: a recent Cochrane review found overall benefits of viscosupplementation in comparison to placebo for pain, function, and patient global assessment scores [9]. But there are also some other clinical trials and reviews that report fewer or inconsistent beneficial effects [10, 11].

In general, an excellent safety profile for this treatment method has been widely shown, with few common adverse events, such as mild injection site pain and swelling [12–16]. However, there are several adverse effects that may occur in either poor injection technique or patients with preexisting morbidities [17, 18]. While periarticular complications are the most common, with an incidence until 43%, intraarticular adverse react (2%–10%) and in particular infections (0.001%–0.072%) are the most dangerous [19].

In this report, we describe a case of a man who received an intra-articular hyaluronate injection for knee OA and developed a severe articular infection and systemic sepsis.

2. Case Presentation

The patient is a 59-year-old male affected by bilateral knee OA. He has already been subjected to surgical intervention
of total hip arthroplasty for Hip OA. Past medical features included a severe obesity, with a body mass index higher than 32, chronic bronchial asthma treated with steroid drugs, and systemic arterial hypertension treated with $\beta$-blockers. VAS score corresponded to 8-9.

Knee X-rays had shown specific characters of articular OA that we could categorize as grade 3 of disease according to Kellgren-Lawrence scale [20].

His right knee pain was difficult to control with conservative measures, including NSAIDs and narcotics. Oral steroid drugs were improved by his family physician in order to get pain relief but with no benefits.

So he was submitted to an intra-articular hyaluronate injection, without immediate complications. A high molecular weight hyaluronic acid has been used (about 1200 kDa). Cleaning technique was employed prior to the treatment, including the use of antiseptic solution and sterile gloves; sterile infiltrative practice in clean condition has been conducted.

About 48 hours after that, he reported a severe fever, at about 102.2 Fahrenheit/$39^\circ$ Celsius. Antipyretic drugs did not decrease body temperature and in a few hours his general clinical conditions got worse.

72 hours after the injection, he was hospitalized. The input diagnosis was septic shock, which was quickly treated with adequate antibiotic and support therapy. CRP and ESR values reported a gradual reduction and the shock had a quick remission.

Blood and knee synovial fluid cultures had clear and dramatic positive results for two different atypical microorganisms: multiresistant *Escherichia Coli* and multiresistant *Klebsiella*.

Specific antibiogram had shown sensitivity to very few antibiotics for this kind of bacteria. A combination of Vancomycin (500 mg I.V., 4 times a day) and Cephalosporin (Ceftriaxone 2gr I.V., twice daily) was used for the full treatment.

Anyway, twelve days after admission, the patient presented a complete flaccid paralysis. An encephalic and spinal MRI was performed, showing a septic involvement of more than two vertebrae, in particular from C5 to C7, and the corresponding cervical spinal cord (Figure 1).

The patient was mainly assisted by the Spinal Unit of our hospital which cooperated with the orthopedic team.

Neurologists performed a proper evaluation of spinal function by the ASIA Standard Neurological Classification of Spinal Cord Injury [21]: results were auspicious. In fact, he did not report any positive response to stimulation and paralysis was complete and permanent.

He has been treated with an intensive rehabilitation program for several weeks.

Meanwhile, he presented a fistula in the proximal region of the leg. So, a new knee X-ray and an MRI were conducted: a severe septic arthritis of the knee and osteomyelitis of tibia and femur were confirmed (Figure 2).

Surgical debridement of the knee and the leg was performed in order to reduce their septic involvement.

Despite his rehab program, the patient did not report any neurological improvements; at a 5-week follow-up, a new cephalic and cervical MRI showed worse conditions: septic features have been found in cerebral ventricles, and spinal disease became larger than before: almost the full cervical spine (C2–C7) was involved by the infection (Figure 3).

The higher spinal cord involvement has made self-contained breathing impossible. Thus, the patient started artificial breathing.

At about four months from the entrance to the hospital, breath complications arose, which led to a poor prognosis. The patient died because of severe acquired pneumonia, caused by *Pseudomonas aeruginosa*.

### 3. Discussion

As mentioned, sodium hyaluronate injection has been proven to be quite safe, with low incidence of adverse reaction [16, 22]. Septic arthritis is a rare but potentially fatal [8, 23–25] severe complication after an intra-articular injection. Although injective practice is conducted in sterile ways, the incidence of joint infection is estimated to be 0.01%–0.072% [19]. In scientific literature, there are several reports about infections for this kind of treatment [8, 16–26]. The causative bacteria could be aerobic, anaerobic, or mixed flora; *S. Aureus* is the most common [27]. Risk factors for joint infections include immunosuppression, diabetes, trauma, and operative infections. Sodium hyaluronate injection is contraindicated if skin disease or current infection is present at the injection
Apart from complications, the debate about long-term effectiveness of intra-articular hyaluronate for OA is always open [9, 11, 35–38].

Several studies show overall benefits for this kind of treatment: it could be considered a viable option in younger patients with less severe disease [9, 35, 36], though some other systematic reviews did not succeed in proving efficacy of hyaluronate joint injection for regression of articular damage [11, 37, 38].

4. Conclusion

The overall incidence of side effects of hyaluronate acid intra-articular injection is lower than 3% [19]. Even if adverse events are quite rare, septic arthritis could be a life-threatening complication. We have presented a case report that underlines the importance of the accurate evaluation of clinical history and comorbidities and the need of clear informed consensus for every invasive treatment, including joint injection. Furthermore, we recommend clear internationally accepted guidelines for clean methods regarding intra-articular injections.

Competing Interests

The authors declare that they have no competing interests.

References

[1] G. S. Dulay, C. Cooper, and E. M. Dennison, “Knee pain, knee injury, knee osteoarthritis & work,” Best Practice and Research: Clinical Rheumatology, vol. 29, no. 3, pp. 454–461, 2015.

[2] Y. Zhang and J. M. Jordan, “Epidemiology of osteoarthritis,” Rheumatic Disease Clinics of North America, vol. 34, no. 3, pp. 515–529, 2008.

[3] T. Y. Ammar, T. A. P. Pereira, S. L. L. Mistura, A. Kuhn, J. I. Saggion, and O. V. Lopes Júnior, “Viscosupplementation for treating knee osteoarthritis: review of the literature,” Revista Brasileira de Ortopedia, vol. 50, no. 5, pp. 489–494, 2015.

[4] S. P. Yu and D. J. Hunter, “Managing osteoarthritis,” Australian Prescriber, vol. 38, no. 4, pp. 113–119, 2015.

[5] D. J. Hunter, “Lower extremity osteoarthritis management needs a paradigm shift,” British Journal of Sports Medicine, vol. 45, no. 4, pp. 283–288, 2011.

[6] A. Migliore, E. Bizzi, J. Herrero-Beaumont, R. J. Petrella, R. Raman, and X. Chevalier, “The discrepancy between recommendations and clinical practice for viscosupplementation in osteoarthritis: mind the gap!,” European Review for Medical and Pharmacological Sciences, vol. 19, no. 7, pp. 1124–1129, 2015.

[7] B. A. McArthur, C. J. Dy, P. D. Fabricant, and A. Gonzalez Della Valle, “Long term safety, efficacy, and patient acceptability of hyaluronic acid injection in patients with painful osteoarthrits of the knee,” Patient Preference and Adherence, vol. 2012, no. 6, pp. 905–910, 2012.

[8] S. Virupannavar and C. Guggenheim, “A Patient with fatal necrotizing fasciitis following the use of intra-articular sodium hyaluronate injections: a case report,” Case Reports in Medicine, vol. 2013, Article ID 531794, 4 pages, 2013.
[9] N. Evaniew, N. Simunovic, and J. Karlsson, “Cochrane in CORR*: viscosupplementation for the treatment of osteoarthritis of the knee,” Clinical Orthopaedics and Related Research, vol. 472, no. 7, pp. 2028–2034, 2014.

[10] S. P. Yu and D. J. Hunter, “Managing osteoarthritis,” Australian Prescriber, vol. 38, no. 4, pp. 115–119, 2015.

[11] A. W. S. Rutjes, P. Jüni, B. R. da Costa, S. Trelle, E. Nüesch, and S. Reichenbach, “Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis,” Annals of Internal Medicine, vol. 157, no. 3, pp. 180–191, 2012.

[12] T. E. Clegg, D. Caborn, and C. Mauffrey, “Viscosupplementation with hyaluronic acid in the treatment for cartilage lesions: a review of current evidence and future directions,” European Journal of Orthopaedic Surgery and Traumatology, vol. 23, no. 2, pp. 119–124, 2013.

[13] J. F. R. Hammesfahr, A. B. Knopf, and T. Stittik, “Safety of intra-articular hyaluronates for pain associated with osteoarthritis of the knee,” American Journal of orthopedics (Belle Mead, N.J.), vol. 32, no. 6, pp. 277–283, 2003.

[14] M. M. Cohen, R. D. Altman, R. Hollstrom, C. Hollstrom, C. Sun, and B. Gipson, “Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan®) in a randomized, double-blind study for osteoarthritis of the ankle,” Foot and Ankle International, vol. 29, no. 7, pp. 657–663, 2008.

[15] P. Jüni, S. Reichenbach, S. Trelle et al., “Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial,” Arthritis & Rheumatism, vol. 56, no. 11, pp. 3610–3619, 2007.

[16] C. Peterson and J. Hodler, “Adverse events from diagnostic and therapeutic joint injections: a literature review,” Skeletal Radiology, vol. 40, no. 1, pp. 5–12, 2011.

[17] P. Courtney and M. Doherty, “Joint aspiration and injection,” Best Practice and Research: Clinical Rheumatology, vol. 19, no. 3, pp. 345–369, 2005.

[18] F. G. O’Connor, “Common injections in sports medicine: general principles and specific techniques,” in Sports Medicine: Just the Facts, F. G. O’Connor, Ed., pp. 426–433, McGraw-Hill Medical, New York, NY, USA, 2005.

[19] M. B. Stephens, A. I. Beutler, and F. G. O’Connor, “Musculoskeletal injections: a review of the evidence,” American Family Physician, vol. 78, no. 8, pp. 971–976, 2008.

[20] J. H. Kellgren, M. JeVrey, and J. Ball, Atlas of Standard Radiographs, vol. 2, Blackwell Scientific, Oxford, UK, 1963.

[21] American Spinal Injury Association, “Standard neurological classification of spinal cord injury,” Continuum, vol. 17, no. 3, pp. 644–645, 2011.

[22] D. H. Neustadt, “Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan®) in patients with osteoarthritis of the knee,” Clinical and Experimental Rheumatology, vol. 21, no. 3, pp. 307–311, 2003.

[23] A. Lim, D. Speers, and C. Inderjeeth, “Cladophialophora (Xylohypha) bantiana—an unusual cause of septic arthritis,” Rheumatology, vol. 52, no. 5, pp. 958–959, 2013.

[24] T. Konkel, T. Schaberg, H. Döll, and M. Schulte, “SIRS and ARDS as a result of drug injection in the shoulder region,” Unfallchirurg, vol. 111, no. 6, pp. 448–454, 2008.

[25] M.-L. Kortelainen and T. Särkioja, “Fatal complications of intramuscular and intra-articular injections,” Zeitschrift für Rechtsmedizin, vol. 103, no. 7, pp. 547–554, 1990.

[26] J. Bento-Rodrigues, F. Judas, J. Pedrosa Rodrigues et al., “Necrotizing fasciitis after shoulder mobilization and intra-articular infiltration with betametasone,” Acta Medica Portuguesa, vol. 26, no. 4, pp. 456–459, 2013.

[27] S. Trouillet-Assant, L. Lelièvre, P. Martins-Simós et al., “Adaptive processes of Staphylococcus aureus isolates during the progression from acute to chronic bone and joint infections in patients,” Cellular Microbiology, vol. 18, no. 10, pp. 1405–1414, 2016.

[28] Hyalgan, Fidia Pharma, Parsippany, NJ, USA, 2011.

[29] W. H. Reinhart, “Corticosteroid therapy,” Praxis, vol. 94, no. 7, pp. 239–243, 2005.

[30] J. J. Rinehart, S. P. Balcerzak, A. L. Sagone, and A. F. LoBuglio, “Effects of corticosteroids on human monocyte function,” Journal of Clinical Investigation, vol. 54, no. 6, pp. 1337–1343, 1974.

[31] Y. M. Arabi, S. I. Dara, H. M. Tamim et al., “Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: an international multicenter cohort study,” Critical Care, vol. 17, no. 2, article R72, 2013.

[32] S. Thelwall, P. Harrington, E. Sheridan, and T. Lamagni, “Impact of obesity on the risk of wound infection following surgery: results from a nationwide prospective multicentre cohort study in England,” Clinical Microbiology and Infection, vol. 21, no. 11, pp. 1008.e1–1008.e8, 2015.

[33] M. C. Hochberg, R. D. Altman, K. T. April et al., “American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee,” Arthritis Care and Research, vol. 64, no. 4, pp. 465–474, 2012.

[34] L. Punzi, M. A. Cimmino, L. Frizziero et al., “Italian Society of Rheumatology (SIR) recommendations for performing arthrocentesis,” Reumatismo, vol. 59, no. 3, pp. 227–234, 2007.

[35] N. Bellamy, J. Campbell, V. Robinson, T. Gee, R. Bourne, and G. Wells, “Viscosupplementation for the treatment of osteoarthritis of the knee,” The Cochrane Database of Systematic Reviews, no. 2, Article ID CD005321, 2006.

[36] W. Zhang, G. Nuki, R. W. Moskowitz et al., “OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009,” Osteoarthritis and Cartilage, vol. 18, no. 4, pp. 476–499, 2010.

[37] P. Jüni, A. W. Rutjes, B. R. da Costa, and S. Reichenbach, “Viscosupplementation for osteoarthritis of the knee,” Annals of Internal Medicine, vol. 158, no. 1, p. 75, 2013.

[38] E. Ayhan, H. Kesmezacar, and I. Akgun, “Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis,” World Journal of Orthopaedics, vol. 5, no. 3, pp. 351–361, 2014.